Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
You may also be interested in...
The company, in the midst of a leadership and structural transition, said the pandemic negatively impacted revenues by about $600m.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.